Nabi Biopharmaceuticals of Boca Raton, Fla., has stated that it is on track with its plans to conduct a Phase II clinical trial of its experimental stop-smoking vaccine at three colleges in the United States. Called NicVAX, the product is in the last steps of a Phase I clinical trial in the Netherlands, with 21 smokers and nine non-smokers receiving a series of injections of the vaccine to determine its safety and effectiveness at different dosage strengths. The three trial sites will enroll a total of 63 patients, funded largely by a grant of $4 million from the National Institute on Drug Abuse.